P276-00 + gemcitabine + carboplatin

P276-00 + gemcitabine + carboplatin is an investigational combination therapy comprising three agents: - **P276-00** is a potent small molecule inhibitor of cyclin-dependent kinases (CDK4-D1, CDK1-B, and CDK9-T), developed as a targeted anti-cancer agent. It acts by inhibiting key regulators of cell cycle progression and transcription, particularly relevant in cancers characterized by cyclin D1 overexpression such as mantle cell lymphoma (MCL)[1][3]. - **Gemcitabine** is a nucleoside analog used as chemotherapy that inhibits DNA synthesis. - **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis. The rationale for combining these drugs stems from the potential synergistic cytotoxic effects observed in preclinical studies when CDK inhibitors are paired with standard chemotherapies. This combination has been explored in clinical trials for advanced solid tumors, including metastatic triple-negative breast cancer[5], but remains investigational.